A Study Of Ursolic Acid For Primary Sclerosing Cholangitis

Status Withdrawn

Clinical Trial Summary

This is an open-label, active treatment trial to determine the pharmacokinetics of orally administered ursolic acid and to assess the potential efficacy and safety of ursolic acid in subjects with primary sclerosing cholangitis (PSC).

Clinical Trial Description

In the first phase of this trial, 6 healthy subjects and 2 PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg to determine the optimal dose in humans.

The second phase of this trial will involve 20 PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03216876
Study type	Interventional
Source	University of California, Davis
Contact
Status	Withdrawn
Phase	Phase 1
Start date	September 2017
Completion date	July 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239211` - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	Phase 2
Recruiting	`NCT02605213` - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Phase 4
Recruiting	`NCT01688024` - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis	Phase 2
Completed	`NCT03041662` - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed	`NCT05866809` - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis	Phase 2
Recruiting	`NCT05618145` - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting	`NCT02446665` - Disease Status in Primary Sclerosing Cholangitis by Elastography	N/A
Completed	`NCT02247934` - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)	N/A
Terminated	`NCT01142323` - Pilot Study of Fenofibrate for PSC	Phase 1/Phase 2
Completed	`NCT01088607` - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis	Phase 1
Terminated	`NCT04060147` - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis	Phase 1
Recruiting	`NCT04133792` - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)	Phase 3
Active, not recruiting	`NCT04595825` - CM-101 in PSC Patients -The SPRING Study	Phase 2
Recruiting	`NCT03183570` - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT	Early Phase 1
Completed	`NCT02943460` - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis	Phase 2
Completed	`NCT00951327` - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)	N/A
Completed	`NCT04024813` - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC	Phase 2
Recruiting	`NCT05912387` - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study	Early Phase 1
Completed	`NCT02884557` - NKT Role in the Regulation of the Inflammatory Bowel Disease	N/A
Recruiting	`NCT01398917` - Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis	Phase 3